Post by PharmaShots

𝗧𝗼𝗽 𝟮𝟬 𝗕𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮 𝗗𝗲𝗮𝗹 𝗧𝗲𝗿𝗺𝗶𝗻𝗮𝘁𝗶𝗼𝗻𝘀 𝗼𝗳 𝟮𝟬𝟮𝟱 💥   Not every billion-dollar deal makes it to the finish line. 2025 revealed a tougher reality for biopharma partnerships, where even the most promising collaborations unraveled under pressure. Strategic resets, competitive intensity, clinical setbacks, and unmet closing conditions reshaped the dealmaking landscape in real time.   What stood out? R&D-led collaborations dominated the termination list, especially across oncology, immunology, and next-gen modalities like cell & gene therapies and RNA platforms. The message is clear: innovation remains the biggest opportunity… and the biggest risk.   Some of the biggest shocks: 🔹 Novo Nordisk–Metsera (~$10B) 🔹 Calico–AbbVie (~$3.5B) 🔹 Lundbeck–Avadel (~$2.4B)   These aren’t just failed deals, they reflect pipeline reprioritization, evolving therapeutic bets, and the constant recalibration of risk vs. reward.   📊 This analysis breaks down the Top 20 terminated deals of 2025, ranked by total value, offering a lens into where and why strategic bets fell apart.   Because in biopharma, knowing what didn’t work is just as critical as knowing what did.   👉 Explore the full breakdown and insights with PharmaShots. • Subscribe to get our LinkedIn newsletter PharmaShots Lens for more insights like this: https://lnkd.in/eyKHSHQy • Subscribe to get our Weekly Newsletter every Monday at 8 AM EST: https://lnkd.in/gTU62Zbz • Connect with me for more insights like this: https://lnkd.in/eb4rky97 Follow PharmaShots for more global industry insights. • On LinkedIn: https://lnkd.in/e4F3D3qK • Other social media platforms: https://lnkd.in/gwNWMQj5 Share this with your friends and colleagues who work in biopharma, healthcare, medtech, diagnostics, and digital health Metsera, Pfizer, Novo Nordisk, Calico Life Sciences, AbbVie, Avadel Pharmaceuticals PLC, Lundbeck, Shoreline Biosciences, Inc., Kite Pharma, Gilead Sciences, Adaptive Biotechnologies Corp., Genentech, Roche, iTeos Therapeutics, GSK, Affinia Therapeutics, Vertex Pharmaceuticals, Amgen, CytomX Therapeutics, Silence Therapeutics plc, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Biond Biologics Ltd, Sanofi, Sutro Biopharma, Inc., Ipsen, Yuhan Corporation, Boehringer Ingelheim, Agenus, Incyte, Nxera Pharma, Heartseed Inc., Sage Therapeutics, Supernus Pharmaceuticals, Inc., Biogen, Fulcrum Therapeutics, MyoKardia, Bristol Myers Squibb, HOOKIPA Pharma Inc., Xencor, Mayne Pharma   #Biopharma #PharmaIndustry #DealMaking #Licensing #MergersAndAcquisitions #Oncology #Immunology #CellTherapy #GeneTherapy #RNA #Biotech #PharmaInsights #ClinicalTrials #DrugDevelopment #LifeSciences #HealthcareInnovation #PharmaTrends #BusinessStrategy #PharmaShots https://lnkd.in/g8s6-nDz